Key strengths of the reviewed paper (evidence-linked)

• Comprehensive synthesis of clinical milestones (notably G47Δ conditional approval in Japan) and translational hotspots: immuno-virotherapy, combination regimens, and delivery innovations Bibliometric roadmap (2025)
• Balanced presentation of diverse viral backbones and explicit discussion of mechanistic links to immunity (ICD, antigen release, myeloid-rich TME) referenced across oHSV, adenovirus, PVSRIPO, VSV, vaccinia and others OV + microbiome review (2024)

Primary criticisms, blindspots and methodological cautions

1. Over-reliance on aggregated trial signals without standardized effect-size synthesis: many claims are qualitative and the field suffers publication and positive-result bias; bibliometrics track activity not clinical efficacy Bibliometric limitations
2. Insufficient emphasis on neutralizing antibodies and pre-existing immunity as a limiting clinical factor — though the review mentions it, deeper integration of human humoral data (e.g., Delta-24-RGD NAb dynamics) is needed to explain route/dosing outcomes NAbs limit adenoviral OV efficacy (2023)
3. Under-discussion of spatial resistance mechanisms such as the tumor self-rampart (IL-8 / senescence / fibrosis) that can restrict intratumoral spread — important when interpreting single-injection intratumoral results IL-8 tumor self-rampart (2025)
4. Limited operational guidance on biomarkers for patient selection — paper notes IDH/MGMT are poor predictors and suggests interferon-pathway status or receptor expression as candidates but gives no actionable biomarker pipeline Biomarker gap for OV (2025)
5. Translational gap from preclinical immunocompetent models to human GBM: many preclinical enhancements (rapamycin, TGF-β modulation, CED, carrier cells) have strong mechanistic rationale but mixed clinical translation; the review should weight preclinical vs clinical evidence more explicitly TGF-β modulates innate clearance (2015)

Recreated figure — Route & dose tradeoffs (preclinical data synthesis)

Support: intratumoral dosing often increases local immunogenic cell death and reduces distant foci but can cause edema/necrosis that inflates MRI tumor volume measures; intravenous dosing risks secondary foci and rapid clearance but can distribute to multifocal disease — findings reflected in vaccinia and VV-GMCSF-Lact animal studies Vaccinia VV-GMCSF-Lact route comparison (2025)

Practical, evidence-based recommendations (explicit)

• Prioritize trials that include prespecified biomarkers of antiviral state (tumor IFN pathway genes, BCL10/IL-8 spatial markers, viral receptor expression like CD155 for PVSRIPO) with baseline and on-treatment sampling IDH affects oHSV responses (2025)
• Design combination arms with rational immunomodulators (e.g., anti-PD1 or macrophage-targeting agents) but include mechanistic endpoints: intratumoral TCR clonality, myeloid phenotyping, spatial transcriptomics to detect TSR-like barriers VSV resistance and combination rationale (2024)
• Report neutralizing antibody kinetics and prior Ad/VSV serostatus; consider capsid engineering or chimeric serotypes for repeat dosing (Delta-24-RGD-H43m data show clinical relevance) Adenovirus NAb evidence (2023)

Confidence, limitations & what would change conclusions

Current conclusion (moderate confidence): OV is a promising, rapidly evolving modality for GBM with real clinical signals (G47Δ approval, DNX-2401 + PD‑1 responses, PVSRIPO durable survivors), but durable, reproducible population-level efficacy remains unproven and critically depends on delivery, immune-escape (NAbs, TSR), and patient molecular context (IDH/IFN pathways). Key evidence that would overturn this conclusion: large randomized trials showing no OS/PFS benefit for OV+combination arms versus SOC across biomarker-stratified cohorts, or consistent safety/lack-of-delivery across multi-center CED/IV trials. Key data that would strengthen the conclusion: reproducible randomized improvements in OS/PFS with biomarker-guided OV arms and validated companion diagnostics for IFN/receptor/IL-8 signatures.

Run deeper analyses